Tumor Treating Fields Boost Pancreatic Cancer Survival

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was associated with significantly improved overall survival in a phase 3 trial for patients with unresectable, locally advanced, pancreatic adenocarcinoma (LA-PAC).
The PANOVA-3 trial 'establishes tumor treating fields with gemcitabine/nab-paclitaxel as a potential new standard treatment paradigm for unresectable, locally advanced pancreatic cancer,' reported Vincent J. Picozzi, MD, first author of the new research, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
The new study, which was simultaneously published in the Journal of Clinical Oncology , is the first phase 3 trial to show an overall survival (OS) benefit for any treatment added to standard chemotherapy in this patient population, where the current 5-year OS rate is less than 8%, said Picozzi in his presentation.
TTFields is a non-invasive therapy that delivers electricity to the tumor site via a wearable device and transducer arrays placed on the skin. The electric fields 'disrupt processes critical for cancer cell division and may do a variety of other things, such as trigger an enhanced anti-tumor response,' he explained. The therapy has already been approved in the United States and Europe for use in various cancers, including glioblastomas, metastatic pleural mesothelioma, and metastatic non-small cell lung cancer (NSCLC).
Study Methods
The open-label study, conducted across 20 countries and 196 sites, included 571 patients with unresectable, locally advanced, biopsy-confirmed, and previously untreated pancreatic adenocarcinoma. Participants had a life expectancy of at least 3 months and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2.
The patients (median age 67 years, 47.6% male) were randomly assigned to receive only gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 by intravenous infusion once a day on days 1, 8, and 15 of a 28-day cycle (n = 286), or the same chemotherapy plus TTFields (n = 285). Patients wore the devices about 15 hours per day for about 28 weeks on average.
Notably, almost 30% of the patients were non-White, almost 4% were ECOG PS 2, 'and perhaps most importantly, almost 30% had CA 19-9 levels greater than 1000, suggesting a high incidence of occult, unrecognized metastatic disease,' said Picozzi, a hematologist-oncologist and director of the Pancreaticobiliary Program at Virginia Mason Medical Center, Seattle, Washington.
Follow-up visits were every 4 weeks, with chest, abdomen, and brain CT or MRI performed every 8 weeks to assess disease progression.
Study Results
After a median follow-up of about 13 months, the primary endpoint of OS was statistically improved in the TTFields arm compared with controls (16.2 vs 14.2 months, hazard ratio [HR] 0.82, P = .039), and the 1-year survival rate was similarly better (68.1% vs 60.2%; P = .029).
There was no significant difference between groups in median progression-free survival (PFS), at 10.6 vs 9.3 months, respectively. However, the 1-year PFS rate was higher in the TTFields arm (43.9% vs 34.1%, P = .026).
'Perhaps somewhat surprisingly,' a post-hoc analysis showed a statistically significant benefit to TTFields in distant PFS, Picozzi said.
Importantly, TTFields showed benefit in quality of life.
'In pain-free survival, another secondary endpoint — which really is freedom from progression of pain over time — we see a very distinct difference' (median 15.2 vs 9.1 months, 1-year pain-free survival rate 54.1% vs 45.1%), he reported.
'Pain is a common and debilitating morbidity in patients with advanced pancreatic adenocarcinoma and a predictor of survival. Thus, by mitigating cancer pain, TTFields may preserve the quality of life of patients with LA-PAC, further supporting TTFields' utility as first-line treatment of this disease,' the authors write in the paper.
Patients also performed quality-of-life analyses using the EORTC QLQ-C30 questionnaire, along with the pancreatic cancer–specific PAN26 addendum, 'and using these tools, there was an improvement in deterioration of global health status, pain, and digestive problems,' said Picozzi.
Most serious adverse events (SAEs), occurring in 53.6% of the TTFields arm and 48% of controls, were related to chemotherapy or the underlying disease, and were not device-related, the authors wrote.
The most common SAEs, which were relatively balanced between arms, were sepsis (6.9% TTFields vs 9.5% controls), cholangitis (5.8% vs 3.7%), bile duct obstruction (5.5% vs 3.3%), and pneumonia (5.1% vs 3.3%), which is a toxicity profile expected for gemcitabine/nab-paclitaxel, Picozzi said.
Most device-related AEs were mild-to-moderate skin reactions, consistent with previous trials of TTFields, and could be managed with topical steroids and calcineurin cream.
In total, 23 patients (8.4%) had device-related AEs leading to TTFields discontinuation, while discontinuation of chemotherapy due to chemotherapy-related AEs occurred in 17.2% in the TTFields group and 15.8% of controls.
Pros and Cons of the Device
Study discussant Brian M. Wolpin, MD, a medical oncologist and director of the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute, Boston, Massachusetts, said, 'Assuming appropriate regulatory approvals, I think the combination of the survival increase and quality-of-life benefits suggests this could be an approach that we could use in patients with locally advanced pancreatic cancer.'
But 'there are some lifestyle constraints of wearing the device 18 hours a day continuously for months,' he noted.
Wolpin's comments also raised the question of whether TTFields could be combined with other first-line choices for LA-PAC, and pointed out that some oncologists treat locally advanced disease with chemotherapy other than gemcitabine/nab-paclitaxel.
'Many of the newer trials have now started to use multi-agent chemotherapy, many different chemotherapy programs, and different lengths of chemotherapy...Some of these trials have used radiation, some have not,' he said.
Indeed, the addition of radiation to first-line chemotherapy for LA-PAC is 'very, very routine' in the United States, Michael Chuong, MD, told Medscape Medical News .
Nevertheless, Chuong, a professor of radiation oncology at Florida International University in Miami and medical director of radiation oncology at Miami Cancer Institute, called PANOVA-3's results exciting.
'The use of chemotherapy, plus any other non-chemo treatment, has never before shown a survival difference,' he said. 'For example, randomized trials of chemotherapy, plus or minus definitive radiation therapy, showed only differences in local control. I would say [this trial] definitely is going to lead to this becoming a standard-of-care option now. Whether all patients with locally advanced pancreatic cancer should be getting this remains to be seen.'
He said the trial's ad hoc finding of statistically significant benefit for TTFields in distant PFS — but not local PFS — suggests that TTFields may be most effective at delaying metastasis.
'If it's delaying onset of liver and peritoneal disease, which almost every one of these patients will ultimately develop, that's huge,' he said, adding that the trial's high number of participants with CA 19-9 levels greater than 1000 suggested a certain amount of metastatic disease in the cohort.
Other TTFields Research Is Ongoing
Chuong is conducting a single-arm, phase 2 study in the same type of population. In his study, TTFields is being combined with stereotactic ablative body radiation (SABR) in the first-line setting, and he has hypothesized that this will delay metastasis.
'From a mechanistic standpoint, this is a treatment that's applied to the entirety of the abdomen. These low electrical fields are delivered to the peritoneum, into the liver, and that's where the predominant site of distant metastatic disease is in these patients.'
The study was funded by Novocure GmbH.
Picozzi disclosed stock and other ownership interests in Amgen, Cigna, Iovance Biotherapeutics, Johnson & Johnson, Lilly, McKesson, and Thermo Fisher; a scientific consulting or advisory role with Revolution Medicines, TriSalus Life Sciences; and research funding from AbbVie, Amal Therapeutics, Astellas Pharma, FibroGen, Ipsen, and NovoCureBrian.
Wolpin disclosed a consulting or advisory role with Agenus, BeiGene, EcoR1 Capital, Harbinger Health, Ipsen, Mirati Therapeutics, Revolution Medicines, Tango Therapeutics, and Third Rock Ventures; and research funding from Amgen (Inst), AstraZeneca (Inst), Harbinger Health (Inst), Lilly (Inst), Novartis (Inst), and Revolution Medicines (Inst).
Chuong disclosed funding from Novocure, Viewray, and Stratpharma.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CNN

8 minutes ago

• CNN

Venice is wild with rumors over the secretive Bezos-Sanchez wedding

Plagued by the looming threat of disruptive protests, the upcoming Venetian wedding of Amazon founder Jeff Bezos and former news anchor and licensed pilot Lauren Sanchez — which is expected to be a lavish, multimillion-dollar affair — may be one of the most anticipated and closely guarded events to be held in the floating city of love. Spokespeople for the couple remain tight-lipped and invited guests have been required to sign NDAs, but a lid cannot be kept on widespread speculation about every detail of the event that is expected to take place this week. At Harry's Bar, a fabled institution that once counted Ernest Hemingway among its customers, the waiters are hoping some of the 200 guests — a mix of A-list celebrities, political dignitaries and powerful business executives — might stop in for one of their famous Bellini cocktails. Whether or not Bezos will bring his yet-unnamed groomsmen there, as George Clooney did when he married Amal Alamuddin in 2014, is anyone's guess. 'We hope so,' one of the waiters told CNN. 'We can't divulge anyone who has made a reservation. We protect the privacy of all of our guests, not just the billionaires.' From the date to the guest list, possible venues and the bridal gown, the rumor mill is spinning at a rapid pace. Proceedings are being overseen by boutique event planners Lanza and Baucina, the Italian duo who transformed Venice's Grand Canal into a red carpet for the Clooneys' glitzy wedding. Protesters believe there's no space for a Bezos wedding in Venice, but the company has insisted that its plans are respectful of the city and the unique set of challenges it faces as one of the most overpopulated tourist sites in Europe. 'Rumors of 'taking over' the city are entirely false and diametrically opposed to our goals and to reality,' they said in a statement shared with CNN. 'From the outset, instructions from our client and our own guiding principles were abundantly clear: the minimizing of any disruption to the city.' The couple is sourcing some 80% of wedding provisions from local vendors, including pastries from the Rosa Salva pastry shop, the oldest in Venice, whose owners told CNN they have been commissioned to create 'about 200 goodie bags.' Murano glassware designer Laguna B also confirmed to CNN that it is creating special party favors. The company declined to share any further details. Veneto regional president Luca Zaia is not concerned about the city's plans to manage the wedding, telling one local paper, 'I repeat, this is a city that handles 150,000 people a day. George Clooney, François-Henri Pinault and Salma Hayek, Alexandre Arnault, Elton John and many others got married here.' He also surmised that the President of the United States, who is scheduled to be in Europe this week for the NATO summit, could conceivably be on the guest list, telling Corriere della Sera, 'Of course, Donald Trump could also come to this wedding.' One imagines that Trump's priorities may have shifted considerably over the weekend. With guests sworn to secrecy about their attendance, Sanchez's very public bachelorette party in Paris last month may offer clues as to who will watch on as she and Bezos say 'I do.' Kim Kardashian, Kris Jenner, Katy Perry, and Eva Longoria all took part in celebrations that included a boat trip along the Seine. Oprah Winfrey, Mick Jagger and Ivanka Trump have also been invited, according to the Associated Press. As is tradition, Sanchez will be keeping details of her wedding gown, and its designer, under wraps until the big day, but close followers of her fashion will know she is a regular wearer of Dolce & Gabbana. Sanchez sat front and center at the Italian house's Alta Moda show in Sardinia last summer as her son Nikko Gonzalez walked the runway, signaling a close relationship with the brand. Others in the running to dress the bride could be the storied house of Oscar de la Renta. Sanchez did not attend this year's Met Gala, but she did notably wear a custom-made gown by the label for her 2024 debut. Around 30 of the city's elite water taxis, out of 280 total, are also thought to be reserved. One taxi driver told CNN he has been booked from June 25th through the 30th for 'a big wedding,' but declined to say more on the subject. Gondolas have also been put on hold, with the city's gondola association confirming they are ready for the event. The city's nine yacht ports have also been booked for the week leading up to the main event. Bezos' $500 million Koru, which is always tailed by the smaller L'Abeona, are both in the Adriatic Sea already, according to the Marine Traffic website. Venice's airspace is closed to drones and non-authorized traffic, but one source told CNN that permission has been granted for private helicopters, particularly for anyone needing special security, such as heads of state. The Marco Polo airport, no stranger to private jet traffic, already has a secluded area with direct access to private water taxis, making it easy for stars to slip into the city unseen. The wedding date itself, by far the most protected detail, still remains unconfirmed and the couple seem hellbent on keeping everyone guessing up until the last minute. A person close to Venice City Hall told CNN that the wedding planners secured a variety of venues over a period of days and will decide what happens where and when based on the most uncontrollable factors — weather and protesters. The wedding is expected to use a small handful of hotels in the city to accommodate guests or host events. One of the most talked-about possible venues is the Cini Foundation on the island of San Giorgio Maggiore, which has hosted everything from G7 events to private concerts. The sculpted gardens and monastery, where monks still pray, sit across the lagoon from the famous Piazza San Marco and would provide an intimate setting ideal for a dinner. Building work being carried out in mid-June looked suspiciously like a set being built — perhaps for a wedding concert? The Aman hotel on the Grand Canal, where the Clooneys chose to wed, has also been mentioned as a potential location. Another top contender is the Scuola Grande della Misericordia, a 16th-century armory that would be perfect for the ceremony itself — although it is more vulnerable to protesters, who have already threatened to block the canals if the wedding party tries to reach the venue. Interestingly, a rather wedding-esque gazebo has been erected next to the Excelsior Hotel on the Venice Lido, a stone's throw from where the Venice Film Festival is held each year. But, as with the rest of the venues, nothing is confirmed.

Yahoo

9 minutes ago

• Yahoo

Should You Buy Gold After Its 60% Increase in Value? Here's What Warren Buffett Has to Say About It.

The value of gold has soared more than 60% since the start of 2024, outpacing the S&P 500. With a weakening dollar and shaky political environment, gold still looks appealing at this price. Buffett and Munger suggest an even better asset for capital preservation. 10 stocks we like better than Berkshire Hathaway › The value of gold has increased faster than both stocks and bonds since the start of 2024 as growing uncertainty has led investors to seek safe havens. Despite the strong performance of the asset, many still feel it could be a great investment today, considering the world's political environment looks just as shaky as ever. But if you ask Warren Buffett if you should invest in gold, the answer is a clear and resounding "No." Analysts at J.P. Morgan disagree. Despite gold climbing about 60% in the last 18 months, they see the precious metal rising another 25% in value through the end of 2026, reaching $4,250 per ounce. But over the long run, there are some very good reasons why the asset will likely underperform stocks. Here's what Buffett thinks about gold, and how long-term investors can easily outperform it. The investment case for gold is that it's a hedge against inflation. If the dollar declines in value (as it has in recent months) the value of gold will increase relative to the dollar. That's because gold is rare. While gold mining companies are constantly digging it out of the ground, the process isn't cheap or easy. Buffett suggests there are much better ways to maintain the value of your dollars. "Gold would be way down on my list as a store of value," he told investors at Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) 2005 annual shareholder meeting. "I would much prefer owning a hundred acres of land here in Nebraska, or an apartment house, or an index fund." Charlie Munger, Berkshire Hathaway's longtime vice chairman and Buffett's friend, was much more blunt. "Gold is a dumb investment," he told the audience. Both of their points were that there are better opportunities, specifically assets that they would call "productive." That is, they have some level of utility beyond looking shiny, being highly conductive, and never corroding (which can be great for jewelry and electronics, but not much else). An ounce of gold will still be an ounce of gold in 100 years. An acre of farmland will still be an acre of land in 100 years. The difference, Buffett says, is that you got to use the land to grow crops and generate income during those 100 years while your ounce of gold probably just sat in a safe somewhere. A good business, like a farm, can protect against inflation because the value of what it produces won't change substantially. As such, in times of inflation, the price of its produce will increase, and the value of the asset will increase as well. Better yet, if you take the income from the asset and reinvest it in expanding (buying more farmland, adding another apartment, finding a new business to start or invest in), you can grow your wealth dramatically. Berkshire Hathaway itself may be the ultimate example. When Buffett took over Berkshire Hathaway in 1965, gold was worth about $35 per ounce. It's increased nearly 100-fold in the 60 years since. Berkshire Hathaway, on the other hand, is up about 58,664-fold. Buffett's advice for average investors is straightforward and simple. The best investment for the average individual is an index fund like the Vanguard S&P 500 ETF (NYSEMKT: VOO). While Buffett points out examples like farmland or apartments, those investments require management to be truly productive. He personally prefers to invest in individual companies. But those require attention as well, even if every publicly traded company has a board of directors and management in place already. If you want returns better than the market average, you'll have to do a lot of work. Even then, the best and brightest minds on Wall Street still struggle most of the time. So, for most people, a passive investment style where you simply buy and hold an index fund works best. A person who consistently adds money saved from their earnings to an index fund portfolio that produces average returns can end up with a level of wealth that's well above average. There's no need to diversify with other asset classes for long-term investors who can weather the ups and downs of the stock market. Even if you agree with J.P. Morgan's analysts that gold will continue to run higher through the end of next year, it's highly unlikely an unproductive asset outperforms a portfolio of productive assets over the long run. Those looking to tame the volatility of stocks may do better with government bonds. Buffett certainly thinks it's a better place to park cash than gold while he looks for Berkshire's next big stock purchase. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Adam Levy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, JPMorgan Chase, and Vanguard S&P 500 ETF. The Motley Fool has a disclosure policy. Should You Buy Gold After Its 60% Increase in Value? Here's What Warren Buffett Has to Say About It. was originally published by The Motley Fool

Washington Post

11 minutes ago

• Washington Post

NATO leaders are set to agree a historic defense spending pledge, but the hike won't apply to all

THE HAGUE, Netherlands — NATO leaders are expected to agree this week that member countries should spend 5% of their gross domestic product on defense, except the new and much vaunted investment pledge will not apply to all of them. Spain has reached a deal with NATO to be excluded from the 5% of GDP spending target , while President Donald Trump said the figure shouldn't apply to the United States, only its allies.